Gene-based delivery of immune-activating cytokines for cancer treatment

Rousseau, 2021, The spectrum of benefit from checkpoint blockade in hypermutated tumors, N. Engl. J. Med., 384, 1168, 10.1056/NEJMc2031965 June, 2018, Chimeric antigen receptor therapy, N. Engl. J. Med., 379, 64, 10.1056/NEJMra1706169 Berraondo, 2019, Cytokines in clinical cancer immunotherapy, Br. J. Cancer, 120, 6, 10.1038/s41416-018-0328-y Atallah-Yunes, 2022, Cytokine based immunotherapy for cancer and lymphoma: biology, challenges and future perspectives, Front. Immunol., 2022 Rosano, 2019, New toolsn in Escherichia coli: a 5-year update, Protein Sci., 28, 1412, 10.1002/pro.3668 Aiuti, 2017, Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products, EMBO Mol. Med., 9, 737, 10.15252/emmm.201707573 Fumagalli, 2022, Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access, Lancet, 399, 372, 10.1016/S0140-6736(21)02017-1 De Palma, 2003, Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells, Nat. Med., 9, 789, 10.1038/nm871 De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 De Palma, 2008, Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis, Cancer Cell, 14, 299, 10.1016/j.ccr.2008.09.004 Kirkwood, 2002, Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy, J. Clin. Oncol., 20, 3703, 10.1200/JCO.2002.03.052 Sato, 2009, Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion, Nat. Med., 15, 696, 10.1038/nm.1973 Escobar, 2014, Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression, Sci. Transl. Med., 6, 10.1126/scitranslmed.3006353 Gentner, 2010, Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy, Sci. Transl. Med., 2, 10.1126/scitranslmed.3001522 Escobar, 2014, Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression, Oncoimmunology, 3, 10.4161/onci.28696 Catarinella, 2016, IFN gene/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment, EMBO Mol. Med., 8, 155, 10.15252/emmm.201505395 Escobar, 2018, Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens, Nat. Commun., 9, 2896, 10.1038/s41467-018-05315-0 Birocchi, 2022, Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models, Sci. Transl. Med., 14, 10.1126/scitranslmed.abl4106 Costa, 2021, A set of cell lines derived from a genetic murine glioblastoma model recapitulates molecular and morphological characteristics of human tumors, Cancers (Basel), 13, 230, 10.3390/cancers13020230 Mucci, 2021, Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses, EMBO Mol. Med., 13, 10.15252/emmm.202013598 Andreou, 2020, Hematopoietic stem cell gene therapy for brain metastases using myeloid cell-specific gene promoters, JNCI J. Natl. Cancer Inst., 112, 617, 10.1093/jnci/djz181 Andreou, 2021, Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model, J. Immunother. Cancer, 9, 10.1136/jitc-2020-001143 Koba, 2013, Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models, PLoS One, 8, 10.1371/journal.pone.0067567 Miyashita, 2016, Immunotherapy against metastatic melanoma with human iPS cell-derived myeloid cell lines producing type I interferons, Cancer Immunol. Res., 4, 248, 10.1158/2326-6066.CIR-15-0096 Satoh, 2003, Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model, Cancer Res., 63, 7853 Brempelis, 2020, Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses, J. Immunother. Cancer, 8, 10.1136/jitc-2020-001356 Kaczanowska, 2021, Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis, Cell, 184, 2033, 10.1016/j.cell.2021.02.048 Parente-Pereira, 2011, Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice, J. Clin. Immunol., 31, 710, 10.1007/s10875-011-9532-8 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin. Cancer Res., 12, 6106, 10.1158/1078-0432.CCR-06-1183 Sundarasetty, 2015, Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma, Gene Ther., 22, 707, 10.1038/gt.2015.43 Wculek, 2019, Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen, J. Immunother. Cancer, 7, 100, 10.1186/s40425-019-0565-5 Goyvaerts, 2015, The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome, Eur. J. Immunol., 45, 3351, 10.1002/eji.201545559 You, 2012, AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications, Oncoimmunology, 1, 847, 10.4161/onci.20504 Chmielewski, 2011, IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression, Cancer Res., 71, 5697, 10.1158/0008-5472.CAN-11-0103 Chmielewski, 2012, CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer, Cancer Immunol. Immunother., 61, 1269, 10.1007/s00262-012-1202-z Markley, 2010, IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice, Blood, 115, 3508, 10.1182/blood-2009-09-241398 Avanzi, 2018, Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system, Cell Rep., 23, 2130, 10.1016/j.celrep.2018.04.051 Zhang, 2021, Gene-edited interleukin CAR-T cells therapy in the treatment of malignancies: present and future, Front. Immunol., 12, 2983 Guedan, 2019, Engineering and design of chimeric antigen receptors, Mol. Ther. Methods Clin. Dev., 12, 145, 10.1016/j.omtm.2018.12.009 Liu, 2017, Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector, Sci. Rep., 7 Mizuguchi, 2000, IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector, Mol. Ther., 1, 376, 10.1006/mthe.2000.0050 Amendola, 2005, Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters, Nat. Biotechnol., 23, 108, 10.1038/nbt1049 Zhang, 2011, Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment, Mol. Ther., 4, 751, 10.1038/mt.2010.313 Webster, 2021, Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models, Mol. Ther., 29, 2691, 10.1016/j.ymthe.2021.05.006 Guo, 2022, Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activation, ACS Synth. Biol., 11, 1440, 10.1021/acssynbio.1c00236 Su, 2016, CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients, Sci. Rep., 6 Schumann, 2015, Generation of knock-in primary human T cells using Cas9 ribonucleoproteins, Proc. Natl. Acad. Sci. U. S. A., 112, 10437, 10.1073/pnas.1512503112 Ma, 2020, Interleukin-23 engineering improves CAR T cell function in solid tumors, Nat. Biotechnol., 38, 448, 10.1038/s41587-019-0398-2 Meister, 2022, Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma, Clin. Cancer Res., 28, 4747, 10.1158/1078-0432.CCR-21-4384 Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol. Ther. Oncolytics., 3, 16011, 10.1038/mto.2016.11 Donnadieu, 2022, Time to evolve: predicting engineered T cell-associated toxicity with next-generation models, J. Immunother. Cancer, 10, 10.1136/jitc-2021-003486 Morello, 2017, MA04.11 mechanistic insights into CAR T-cell efficacy in the treatment of heterogenous antigen expressing lung adenocarcinoma, J. Thorac. Oncol., 12, S363, 10.1016/j.jtho.2016.11.405 O’Cearbhaill, 2020, A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC), Gynecol. Oncol., 159, 42, 10.1016/j.ygyno.2020.06.089 Yang, 2012, IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma, J. Clin. Invest., 122, 1271, 10.1172/JCI59806 Greenshpan, 2021, Synthetic promoters to induce immune-effectors into the tumor microenvironment, Commun. Biol., 4, 1, 10.1038/s42003-021-01664-7 Kosti, 2021, Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors, Cell Reports Med., 2, 10.1016/j.xcrm.2021.100227 Hurton, 2016, Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells, Proc. Natl. Acad. Sci. U. S. A., 113, E7788, 10.1073/pnas.1610544113 Shum, 2017, Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells, Cancer Discov., 7, 1238, 10.1158/2159-8290.CD-17-0538 Zhang, 2015, Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma, Clin. Cancer Res., 21, 2278, 10.1158/1078-0432.CCR-14-2085 Watanabe, 2018, Oncolytic virotherapy by HSV, Adv. Exp. Med. Biol., 1045, 63, 10.1007/978-981-10-7230-7_4 Rodriguez, 1997, Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells, Cancer Res., 57, 2559 Fukuda, 2003, E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer, Cancer Res., 63, 4434 Hajeri, 2020, Oncolytic adenoviruses: strategies for improved targeting and specificity, Cancers (Basel), 12, 1504, 10.3390/cancers12061504 Coughlan, 2010, Tropism-modification strategies for targeted gene delivery using adenoviral vectors, Viruses, 2, 2290, 10.3390/v2102290 Barry, 2020, Retargeting adenoviruses for therapeutic applications and vaccines, FEBS Lett., 594, 1918, 10.1002/1873-3468.13731 Andtbacka, 2015, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma, J. Clin. Oncol., 33, 2780, 10.1200/JCO.2014.58.3377 Conry, 2018, Talimogene laherparepvec: first in class oncolytic virotherapy, Hum. Vaccin. Immunother., 14, 839, 10.1080/21645515.2017.1412896 Hu, 2006, A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor, Clin. Cancer Res., 12, 6737, 10.1158/1078-0432.CCR-06-0759 Kaufman, 2010, Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma, Ann. Surg. Oncol., 17, 718, 10.1245/s10434-009-0809-6 Toda, 2000, Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte–macrophage colony-stimulating factor, Mol. Ther., 2, 324, 10.1006/mthe.2000.0130 Kohlhapp, 2016, Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy, Clin. Cancer Res., 22, 1048, 10.1158/1078-0432.CCR-15-2667 Shen, 2016, Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia, Blood, 127, 1449, 10.1182/blood-2015-06-652503 Cook, 2022, Clinical activity of single dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma, Blood Adv., 6, 3268 Bourgeois-Daigneault, 2016, Oncolytic vesicular stomatitis virus expressing interferon-α has enhanced therapeutic activity, Mol. Ther. Oncolytics., 3, 16001, 10.1038/mto.2016.1 Liu, 2018, Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2, Nat. Commun., 9, 4682, 10.1038/s41467-018-06954-z Wang, 2017, Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent, Nat. Commun., 8, 1395, 10.1038/s41467-017-01385-8 Nakao, 2020, Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade, Sci. Transl. Med., 12, 10.1126/scitranslmed.aax7992 Saha, 2017, Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade, Cancer Cell, 32, 253, 10.1016/j.ccell.2017.07.006 Ma, 2021, An oncolytic virus expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma, Cancer Res., 81, 3635, 10.1158/0008-5472.CAN-21-0035 Zheng, 2019, Oncolytic viruses for cancer therapy: barriers and recent advances, Mol. Ther. Oncolytics., 15, 234, 10.1016/j.omto.2019.10.007 Bezeljak, 2022, Cancer gene therapy goes viral: viral vector platforms come of age, Radiol. Oncol., 56, 1, 10.2478/raon-2022-0002 Bin Umair, 2022, Viruses as tools in gene therapy, vaccine development, and cancer treatment, Arch. Virol., 167, 1387, 10.1007/s00705-022-05432-8 Liu, 2010, Advances in viral-vector systemic cytokine gene therapy against cancer, Vaccine, 28, 3883, 10.1016/j.vaccine.2010.03.041 Chiocca, 2019, Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial, Sci. Transl. Med., 11, 10.1126/scitranslmed.aaw5680 Chiocca, 2022, Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial, Neuro-Oncology, 24, 951, 10.1093/neuonc/noab271 Boorjian, 2021, Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial, Lancet Oncol., 22, 107, 10.1016/S1470-2045(20)30540-4 Dinney, 2013, Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer, J. Urol., 190, 850, 10.1016/j.juro.2013.03.030 Morsut, 2016, Engineering customized cell sensing and response behaviors using synthetic Notch receptors, Cell., 164, 780, 10.1016/j.cell.2016.01.012 Zhu, 2022, Modular design of synthetic receptors for programmed gene regulation in cell therapies, Cell., 185, 1431, 10.1016/j.cell.2022.03.023 Cripe, 2022, Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics, Sci. Adv., 8, 10.1126/sciadv.abm1890 Finocchiaro, 2022, OS05.6.A modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109), Neuro-Oncology, 24, ii13, 10.1093/neuonc/noac174.042 Li, 2020, Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity, Nat. Cancer, 1, 882, 10.1038/s43018-020-0095-6 Liu, 2022, Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy, J. Control. Release, 345, 306, 10.1016/j.jconrel.2022.03.021 Carmenate, 2013, Human IL-2 mutein with higher antitumor efficacy than wild type IL-2, J. Immunol., 190, 6230, 10.4049/jimmunol.1201895 Rojas, 2019, Directed evolution of super-secreted variants from phage-displayed human interleukin-2, Sci. Rep., 9, 800, 10.1038/s41598-018-37280-5 Sockolosky, 2018, Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes, Science, 359, 1037, 10.1126/science.aar3246 Zhang, 2021, A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia, Sci. Transl. Med., 13, 10.1126/scitranslmed.abg6986 Aspuria, 2021, An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma, Sci. Transl. Med., 13, 10.1126/scitranslmed.abg7565 Kalbasi, 2022, Potentiating adoptive cell therapy using synthetic IL-9 receptors, Nature, 607, 360, 10.1038/s41586-022-04801-2 Bushman, 2020, Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones, Mol. Ther., 28, 352, 10.1016/j.ymthe.2019.12.009 Tucci, 2022, A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders, Nat. Commun., 13, 1315, 10.1038/s41467-022-28762-2 Zufferey, 1998, Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery, J. Virol., 72, 9873, 10.1128/JVI.72.12.9873-9880.1998 Cesana, 2014, Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo, Mol. Ther., 22, 774, 10.1038/mt.2014.3 Yu, 1986, Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells, Proc. Natl. Acad. Sci. U. S. A., 83, 3194, 10.1073/pnas.83.10.3194 Aiuti, 2013, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, Science, 341, 10.1126/science.1233151 Aiuti, 2009, Ten years of gene therapy for primary immune deficiencies, Hematology, 2009, 682, 10.1182/asheducation-2009.1.682 Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z Papayanni, 2021, Investigating the barrier activity of novel, human enhancer-blocking chromatin insulators for hematopoietic stem cell gene therapy, Hum. Gene Ther., 32, 1186, 10.1089/hum.2021.142 Brog, 2022, Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors, Cancer Immunol. Res., 10, 962, 10.1158/2326-6066.CIR-21-0536 Li, 2022, Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells, Sci. Rep., 12, 1 Batra, 2020, Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma, Cancer Immunol. Res., 8, 309, 10.1158/2326-6066.CIR-19-0293 Bell, 2021, Engineered cytokine signaling to improve CAR T cell effector function, Front. Immunol., 10.3389/fimmu.2021.684642 Heczey, 2020, Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis, Nat. Med., 26, 1686, 10.1038/s41591-020-1074-2 Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood., 119, 4133, 10.1182/blood-2011-12-400044 Koneru, 2015, IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo, Oncoimmunology, 4, 10.4161/2162402X.2014.994446 Dinarello, 2018, Overview of the IL-1 family in innate inflammation and acquired immunity, Immunol. Rev., 281, 8, 10.1111/imr.12621